Adverse events in the nervous system associated with blinatumomab: a real-world study
Age is an independent protective factor for fatal NST, and CRS leads to a higher fatality rate for NST patients treated with blinatumomab. Thorough medication evaluation should be conducted before administering blinatumomab, especially for high-risk patients with preexisting neurological conditions.
Authors
- Lihua Qiu (ORCID: https://orcid.org/0000-0003-4637-1811)
- Yifei Sun (ORCID: https://orcid.org/0000-0002-5841-1262)
- Shiyong Zhou
- Lu Wen (ORCID: https://orcid.org/0000-0002-1773-1876)
- Jingwei Yu (ORCID: https://orcid.org/0000-0002-7587-754X)
- Xianhuo Wang (ORCID: https://orcid.org/0000-0001-8742-4348)
- L Li
- Zhengzi Qian
- Zheng Song (ORCID: https://orcid.org/0000-0002-9495-4459)
- Xue Han (ORCID: https://orcid.org/0000-0001-5569-3113)
- Xia Liu (ORCID: https://orcid.org/0000-0002-9768-2583)
- Huilai Zhang
Institutions
- Tianjin Medical University Cancer Institute and Hospital (CN)
- Fourth People’s Hospital of Jinan (CN)
Publication Details
- Journal
- BMC Medicine
- Published
- 2025-02-06
- DOI
- https://doi.org/10.1186/s12916-025-03913-6
- Citations
- 18
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 18.82
Funders
- National Natural Science Foundation of China